Patient characteristics
. | First cohort . | Second cohort . | Total . |
|---|---|---|---|
| No. patients | 62 | 40 | 102 |
| Recipient age in y, median (range) | 35 (6-56) | 35 (3-55) | 35 (3-56) |
| Recipient age, no. | |||
| Age 25 y or less | 40 | 14 | 54 |
| Age over 25 y | 22 | 26 | 48 |
| Recipient sex ratio, no. female/no. male | 29/33 | 14/26 | 43/59 |
| Diagnosis, no. | |||
| AML | 10 | 11 | 21 |
| CML | 25 | 9 | 34 |
| ALL | 10 | 9 | 19 |
| MDS | 4 | 1 | 5 |
| NHL | 1 | 1 | 2 |
| Hodgkin disease | 1 | 0 | 1 |
| Aplastic anemia | 9 | 3 | 12 |
| Other | 2 | 6 | 8 |
| Disease risk, no. | |||
| Nonmalignant | 10 | 5 | 15 |
| Malignant low risk | 42 | 29 | 71 |
| Malignant intermediate risk | 9 | 6 | 15 |
| Malignant high risk | 1 | 0 | 1 |
| CMV serology, no. | |||
| R+/D+ | 26 | 18 | 44 |
| R+/D- | 8 | 6 | 14 |
| R-/D+ | 5 | 1 | 6 |
| R-/D- | 23 | 15 | 38 |
| ABO, no. | |||
| Compatible | 47 | 30 | 77 |
| Incompatible | 15 | 10 | 25 |
| GVHD prophylaxis, no. | |||
| CSA and MTX | 54 | 38 | 92 |
| CSA and MTX and others | 5 | 0 | 5 |
| CSA with or without others | 3 | 2 | 5 |
| Conditioning regimen, no. | |||
| TBI-based | 19 | 14 | 33 |
| BU-based | 37 | 26 | 63 |
| Median CD34 infused, ×106/kg | 4.2 | 6.2 | 4.7 |
. | First cohort . | Second cohort . | Total . |
|---|---|---|---|
| No. patients | 62 | 40 | 102 |
| Recipient age in y, median (range) | 35 (6-56) | 35 (3-55) | 35 (3-56) |
| Recipient age, no. | |||
| Age 25 y or less | 40 | 14 | 54 |
| Age over 25 y | 22 | 26 | 48 |
| Recipient sex ratio, no. female/no. male | 29/33 | 14/26 | 43/59 |
| Diagnosis, no. | |||
| AML | 10 | 11 | 21 |
| CML | 25 | 9 | 34 |
| ALL | 10 | 9 | 19 |
| MDS | 4 | 1 | 5 |
| NHL | 1 | 1 | 2 |
| Hodgkin disease | 1 | 0 | 1 |
| Aplastic anemia | 9 | 3 | 12 |
| Other | 2 | 6 | 8 |
| Disease risk, no. | |||
| Nonmalignant | 10 | 5 | 15 |
| Malignant low risk | 42 | 29 | 71 |
| Malignant intermediate risk | 9 | 6 | 15 |
| Malignant high risk | 1 | 0 | 1 |
| CMV serology, no. | |||
| R+/D+ | 26 | 18 | 44 |
| R+/D- | 8 | 6 | 14 |
| R-/D+ | 5 | 1 | 6 |
| R-/D- | 23 | 15 | 38 |
| ABO, no. | |||
| Compatible | 47 | 30 | 77 |
| Incompatible | 15 | 10 | 25 |
| GVHD prophylaxis, no. | |||
| CSA and MTX | 54 | 38 | 92 |
| CSA and MTX and others | 5 | 0 | 5 |
| CSA with or without others | 3 | 2 | 5 |
| Conditioning regimen, no. | |||
| TBI-based | 19 | 14 | 33 |
| BU-based | 37 | 26 | 63 |
| Median CD34 infused, ×106/kg | 4.2 | 6.2 | 4.7 |
AML indicates acute myeloid leukemia; CML, chronic myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; TBI, total body irradiation; BU, busulfan; R, recipient; D, donor; CSA, cyclosporine A; MTX, methotrexate.